Major depressive disorder (MDD) is a chronic and recurrent ... of such MDD patients remit following adequate antidepressant treatment, while most MDD patients suffer from significant core ...

The diagnosis of major depressive disorder is based on the patient's ... Typically, patients are treated with antidepressant medication and, in many cases, also receive psychotherapy or counseling ...

Johnson & Johnson has entered an agreement to acquire all outstanding shares of Intra-Cellular Therapies, in a ...

Psilocybin is under clinical development by Filament Health and currently in Phase I for Major Depressive Disorder.

Navacaprant is an highly selective kappa opioid receptor antagonist expected to modulate reward processing pathways and mediate depressive states.

Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage ...

Neumora Therapeutics Inc.’s stock tumbled 80% Thursday, after the clinical-stage biotech said a late-stage trial of a ...

SPL-026 is under development for the treatment of major depressive disorder (MDD). The drug candidate is a psychedelic N,N-dimethyltryptamine (DMT) based medicine. It is administered through i ...

DRIVING under the influence of drink or drugs, including prescription drugs, is usually to blame for cases of dangerous ...

Up to 12 months, psychological interventions showed preventive effects for major depressive disorder reducing symptom severity and incidence.